Semax
- Category
- Brain & Cognition
- Administration routes
- Nasal
- Regulatory status
- Not FDA-approved
What it is
A synthetic peptide (an ACTH(4-10) analog) used intranasally as a nootropic and neuroprotective aid for stroke recovery and focus. Human evidence is moderate at best for stroke neuroprotection and raising BDNF, while cognitive claims rest on weak data. Nearly all studies run only 10 to 14 days, so long-term safety is unknown, and the FDA flagged immunogenicity. It is not an approved drug in the US, and most supply is unregulated research-grade material.
Read Full recordStudied uses & evidence
Studied uses(6)
Neuroprotection and neuroregeneration in ischemic stroke
MediumAn approved stroke therapy in Russia, backed by human trials, though these are mostly open-label rather than blinded.
Cognitive enhancement and nootropic effects
LowSupported by animal learning data and a clear BDNF mechanism, but controlled trials in healthy people are lacking.
BDNF and neurotrophin upregulation for brain health
MediumExtensive animal data show raised BDNF and NGF, with elevated plasma BDNF confirmed in human stroke patients.
Evidence limits
- Evidence Level
- Moderate
Semax's clinical evidence base is moderate and geographically concentrated in Russian institutions. The primary human evidence comes from a clinical trial in 110 ischemic stroke patients showing Semax increased BDNF levels and improved functional recovery (Gusev et al. 2018); 15 years of clinical experience documenting cognitive enhancement in healthy volunteers with effects lasting 20-24 hours and no adverse effects (Ashmarin et al. 1997); a double-blind placebo-controlled study in 30 healthy adults showing improved attention, working memory, and psychomotor speed; and clinical trials demonstrating efficacy in optic nerve diseases including glaucomatous optic neuropathy (Polunin et al. 2000, Kurysheva et al. 2001). Preclinical evidence is substantially more extensive, with genome-wide transcriptomic studies, BDNF/neurotrophin pathway characterization, amyloid-beta aggregation inhibition, and melanocortin receptor pharmacology. Major gaps include the absence of large international RCTs, no long-term safety studies beyond 10-14 day courses, no trials specifically targeting aging or longevity outcomes, and publication of most Russian studies in Russian-language journals with limited international peer review.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Acute psychosis or mania
HighSemax increases BDNF and dopaminergic activity, which may exacerbate psychotic or manic episodes.
General cautions
Pregnancy
AbsoluteNo reproductive safety data outside Russia.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
Most clinical studies examine only 10-14 day treatment courses
ModerateFDA cited immunogenicity as a safety concern
ModerateMild nasal dryness/irritation (intranasal)
LowOccasional mild headaches
LowSingle-dose fatigue-study signal only for some claims
ModeratePossible effects of chronically elevated BDNF
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.